

**Attorney Docket No. 1623-U-05**

TECH CENTER 1600/2900

FEB 15 2002

**Form PTO-SB/08A** U.S. Department of Commerce  
Patent and Trademark Office

Information Disclosure Statement by Applicant

Application No.:09/966,311  
Filing Date: 09/28/2001  
Inventors: Berg, et al.  
Group Art Unit:  
Examiner Name:  
Attorney Docket No.: 1623-U-05

ER 1600/2000  
2002 SEP 1

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	7/24/03
-----------------------	---	--------------------	---------

**\*EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

TECH CENTER 1600/2900

FEB 15 2002

RECEIVED

Form PTO-SB/08B	U.S. Department of Commerce Patent and Trademark Office	Application No.: Filing Date: Inventors: Senior et al. Group Art Unit: Examiner Name: Attorney Docket No.: 1464-U-02
<b>Information Disclosure Statement by Applicant</b>		

<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KSG		BERG, D. et al. Chronic Fatigue Syndrome and/or Fibromyalgia as a Variation of Antiphospholipid Antibody Syndrome: An Explanatory Model and Approach to Laboratory Diagnosis. Blood Coagulation and Fibrinolysis. October 1999, Vol. 10, No. 7, pages 435-438, see entire document.	
1CSJ		KAHN, S.R. et al. Nonvalvular Atrial Fibrillation: Evidence for a Prothrombic State. Can. Med. Assoc. J. September 1997, Vol. 157, No. 6, pages 673-681, see entire document.	
KSS		SAKATA, T. et al. Suppression of Plasma-Activated Factor VII Levels by Warfarin Therapy. Arterioscler. Thromb. Vasc. Biol. February 1995, Vol. 15, No. 2, pages 241-246, see entire document.	
1CSS		TAKAHASHI, H. et al. Evaluation of Oral Anticoagulant Therapy by Measuring Plasma Prothrombin Fragment 1 + 2. Blood Coagulation and Fibrinolysis. 1993, Vol. 4, No. 3, pages 435-439, see entire document.	
KSI		BERG, D.E. et al. Monitoring of Heparin Therapy by Soluble Fibrin Monomer (SFM) Levels in Infertile Women Who Became Pregnant and Carried Their Pregnancies to Full Term Delivery on Heparin: A comparison of Quantitative Versus Semiquantitative Methods for SFM. Blood. 1997, Vol. 90, No. 10, Suppl. 1, Part 2, page 111b. Abstract No. 3206.	
1CS		BONA, R. et al. Thrombin Generation and Activity are Increased in Patients with Cancer Receiving Sodium Warfarin as Secondary Prophylaxis Against Venous Thrombosis. Blood. 1997, Vol. 90, No. 10, Suppl. 1, Part 2, page 111b. Abstract No. 3207.	
KSS		FON, E.A. et al. Hemostatic Markers in Acute Transient Ischemic Attacks. Stroke. February 1994, Vol. 25, No. 2, pages 282-286, see entire document.	
1CS		LIP, G.Y.H. et al. Increased Markers of Thrombogenesis in Chronic Atrial Fibrillation: Effects of Warfarin Treatment. British Heart Journal. 1995, Vol. 73, No. 6, pages 527-533, see entire document.	
1CSS		VECCHI, M. et al. Risk of Thromboembolic Complications in Patients with Inflammatory Bowel Disease. Int. J. Clin. Lab. Res. 1991, Vol. 21, No. 2, pages 165-170, see entire document.	
1CSJ		The Merck Manual of Diagnosis and Therapy. 16 <sup>th</sup> Edition. Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ. Edited by: Berkow, R. et al. 1992, see pages 678-679.	
KSS		The Merck Manual of Diagnosis and Therapy. 16 <sup>th</sup> Edition. Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ. Edited by: Berkow, R. et al. 1992, see pages 154-157, 841-845, 1312-1313, 1402-1407, 1488-1490, 1495-1500, 2102-2105, 2267-2268	
KSJ		US 5,846,758 A (MEDENICA) 08 December 1998, see entire document.	
1CS		US 5,834,215 A (GARRY et al.) 10 November 1998, see entire document.	

Examiner Signature	<i>[Signature]</i>	Date Considered	7/24/03
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.



Attorney Docket No. 1623-H-05

~~RECEIVED~~

**COPY OF PAPERS  
ORIGINALLY FILED**

JUL 22 2002

TECH CENTER 1600/2900

**Form PTO-SB/08B** U.S. Department of Commerce  
Patent and Trademark Office

## **Information Disclosure Statement by Applicant**

**Application No.:**

**Filing Date:**


Inventors: David E. Berg et al..

## **Group Art Unit:**

**Examiner Name:**

**Attorney Docket No.: 1623-U-05**

#### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	7/24/03
--------------------	---	-----------------	---------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.

**BEST AVAILABLE COPY**

RECEIVED

APR 10 2003

Attorney Docket No. 1623-U-05

TECH CENTER 1800/2800



Form PTO-SB/08A	U.S. Department of Commerce Patent and Trademark Office	Application No.:09/966,311 Filing Date: 09/28/2001 Inventors: Berg, et al. Group Art Unit: Examiner Name: Attorney Docket No.: 1623-U-05
<b>Information Disclosure Statement by Applicant</b>		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Mannucci, British Medical Bulletin 50(4):851-870 (1994)	
		Cohen et al., Am. J. Cardiol. 66(19):1287-1292 (1990). Abstract.	

Examiner Signature		Date Considered	7/24/07
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.

BEST AVAILABLE COPY



Attorney Docket No. 1623-U-05

RECEIVED

MAY 22 2003

TECH CENTER 1600/2900

**Form PTO-SB/08A** U.S. Department of Commerce  
Patent and Trademark Office

**Information Disclosure  
Statement by Applicant**

Application No.:09/966,311

Filing Date: 09/28/2001

Inventors: Berg, et al.

Group Art Unit: 1651

Examiner Name:

Attorney Docket No.: 1623-U-05

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		4,451,454		Wong	05/29/1984	
		6,107,280		White et al.	08/22/2000	

**Form PTO-SB/08A** U.S. Department of Commerce  
Patent and Trademark Office

**Information Disclosure  
Statement by Applicant**

Application No.:09/966,311

Filing Date: 09/28/2001

Inventors: Berg, et al.

Group Art Unit: 1651

Examiner Name:

Attorney Docket No.: 1623-U-05

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BERG et al, Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagulation and Fibrinolysis 1999, Vol 10, No. 7, pgs. 435-438.	
		HANNAN et al., Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome - A laboratory approach to diagnosis. Blood Coagulation and Fibrinolysis 2000, Vol 11, No 7, pgs. 673-678.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.

BEST

COPY

BEST AVAILABLE COPY